DKN-01 300 mg

DRUG3 trials

Conditions

Adenocarcinoma of the Gastroesophageal JunctionEsophageal NeoplasmsGastric AdenocarcinomaGastroesophageal CancerHepatocellular CarcinomaMultiple MyelomaSquamous Cell Carcinoma

Phase 1

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01711671

Leap Therapeutics, Inc.Multiple Myeloma

Start: 2013-05-31End: 2015-07-31Updated: 2025-08-03

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

CompletedNCT02013154

Leap Therapeutics, Inc.Adenocarcinoma of the Gastroesophageal Junction, Esophageal Neoplasms, Gastric Adenocarcinoma +2

Start: 2014-05-05End: 2021-01-11Updated: 2025-08-03

DKN-01 Inhibition in Advanced Liver Cancer

NCT03645980

Johannes Gutenberg University MainzHepatocellular Carcinoma

Start: 2018-10-10End: 2022-08-31Target: 70Updated: 2020-10-22

2024-11-014 citations

262 Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01

Regular and Young Investigator Award Abstracts2020-11-01

DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.

Journal of Clinical Oncology2020-02-0117 citations

Correlation of radiomics of metastatic lesions in gastroesophageal adenocarcinoma (GEA) with tumoral DKK1 mRNA expression and other immune biomarkers in patients (pts) treated with DKN-01.

Journal of Clinical Oncology2020-02-01

Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies

Annals of Oncology2018-10-0113 citations

Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.

Journal of Clinical Oncology2017-02-014 citations

Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).

Journal of Clinical Oncology2016-05-206 citations

Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).

Journal of Clinical Oncology2016-02-0116 citations

DKN-01 300 mg

Sponsors

Conditions

Phase 1

Related Papers